Business Context and Reporting Period
This Form 8-K filing by Supernus Pharmaceuticals, Inc. reports on events occurring on March 3, 2015. The filing details the Board of Directors' approval of modifications to the compensatory arrangements for the company's executive officers, effective January 1, 2015.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
Material Changes
The primary material change is the increase in annual base salaries and bonus targets for six executive officers, along with new stock option grants. Specific changes include:
- Jack A. Khattar (CEO): Base salary increased from $486,675 to $525,000. 2014 bonus of $292,000 awarded. 2015 bonus target increased to 60% of base salary (from 50%). Granted options for 250,000 shares.
- Gregory S. Patrick (CFO): Base salary increased from $318,270 to $331,000. 2014 bonus of $118,000 awarded. 2015 bonus target increased to 40% of base salary (from 35%). Granted options for 50,000 shares.
- Stefan K.F. Schwabe (CMO): Base salary increased from $342,860 to $357,000. 2014 bonus of $143,000 awarded. Granted options for 50,000 shares.
- Padmanabh P. Bhatt (CSO): Base salary increased from $324,635 to $338,000. 2014 bonus of $101,000 awarded. Granted options for 30,000 shares.
- Jones W. Bryan (VP Business Development): Base salary increased from $265,225 to $276,000. 2014 bonus of $86,000 awarded. Granted options for 25,000 shares.
- Victor L. Vaughn (SVP Sales): Base salary increased from $283,250 to $292,000. 2014 bonus of $88,000 awarded. 2015 bonus target increased to 35% of base salary (from 30%). Granted options for 35,000 shares.
All stock options have an exercise price of $9.13 per share and vest annually in equal increments over four years.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on business performance, or discussion of risks and contingencies. The compensation changes were the result of the Compensation Committee's annual review.
Investor Verification Checklist
- Verify the total aggregate cost of the new salary increases and bonus targets against the company's cash burn rate.
- Confirm the dilution impact of the 440,000 total new stock options granted.
- Review the company's most recent 10-K or 10-Q for context on cash reserves relative to these increased fixed costs.
- Check if the 2014 bonuses were paid in cash or stock, as this affects immediate liquidity.